Top-Rated Stocks NASDAQ:BCYC Bicycle Therapeutics - BCYC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. $22.40 +2.23 (+11.06%) (As of 03/28/2023 05:12 PM ET) Add Compare Share Share Today's Range$20.78▼$22.5950-Day Range$20.02▼$28.9452-Week Range$12.08▼$50.47Volume520,009 shsAverage Volume315,466 shsMarket Capitalization$477.34 millionP/E RatioN/ADividend YieldN/APrice Target$51.36 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Bicycle Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.85 Rating ScoreUpside/Downside129.4% Upside$51.36 Price TargetShort InterestBearish14.31% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 2 Articles This WeekInsider TradingSelling Shares$279,441 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.72) to ($5.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.68 out of 5 starsMedical Sector866th out of 1,002 stocksPharmaceutical Preparations Industry420th out of 488 stocks 3.4 Analyst's Opinion Consensus RatingBicycle Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.36, Bicycle Therapeutics has a forecasted upside of 129.4% from its current price of $22.39.Amount of Analyst CoverageBicycle Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.31% of the outstanding shares of Bicycle Therapeutics have been sold short.Short Interest Ratio / Days to CoverBicycle Therapeutics has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.Change versus previous monthShort interest in Bicycle Therapeutics has recently decreased by 2.87%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldBicycle Therapeutics does not currently pay a dividend.Dividend GrowthBicycle Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BCYC. Previous Next 1.3 News and Social Media Coverage News SentimentBicycle Therapeutics has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Bicycle Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 2 people have searched for BCYC on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Bicycle Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $279,441.00 in company stock.Percentage Held by InsidersOnly 9.00% of the stock of Bicycle Therapeutics is held by insiders.Percentage Held by Institutions77.88% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($4.72) to ($5.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bicycle Therapeutics is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bicycle Therapeutics is -5.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBicycle Therapeutics has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bicycle Therapeutics (NASDAQ:BCYC) StockBicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.Read More Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCYC Stock News HeadlinesMarch 26, 2023 | americanbankingnews.comAnalysts Set Bicycle Therapeutics plc (NASDAQ:BCYC) Price Target at $51.36March 18, 2023 | msn.comBicycle ridership in Portland has dropped off significantly over past 6 years, PBOT saysMarch 28, 2023 | Investor Place Media (Ad)The "King Of Quants" sees 10X potential...Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...March 1, 2023 | msn.comFuller Center Bicycle Adventure pedals hope to end poverty housingMarch 1, 2023 | markets.businessinsider.comWhat 8 Analyst Ratings Have To Say About Bicycle TherapeuticsFebruary 28, 2023 | msn.comWe are fighting war of attrition with rip-off rivals, says Brompton Bicycle bossFebruary 28, 2023 | forbes.comElectric Bike Battery Collection And Recycling Program Started By U.K.’s Bicycle AssociationFebruary 28, 2023 | msn.comBicycle Therapeutics GAAP EPS of -$1.01 beats by $0.05, revenue of $3.19M misses by $0.56MMarch 28, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …February 28, 2023 | finance.yahoo.comBicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate UpdateFebruary 17, 2023 | finance.yahoo.comBicycle Therapeutics- Solid Cancer Drug Data Reinforces Investment CaseFebruary 15, 2023 | marketwatch.comBicycle Therapeutics Upbeat on Early BT8009 Study Results >BCYCFebruary 15, 2023 | marketwatch.comE-Bicycle Motors Market Analysis Report 2023 Along with Statistics Figures, Forecasts till 2028February 15, 2023 | marketwatch.comRecumbent Bicycle Market Management of Massive Data and Availability to Hamper the Industry GrowthFebruary 14, 2023 | marketwatch.comBicycle Tire Market 2023-2027: Climbs on Positive Latest Outlook of Booming Sales | 133 Pages ResearchFebruary 14, 2023 | finance.yahoo.comBicycle Therapeutics Announces Phase I Dose Escalation Results from Ongoing Phase I/II Study of BT8009February 13, 2023 | marketwatch.comBicycle and Components Market 2023-2025 | Achieving Sustainable Growth: Strategies & Tips | 107 Pages ReportFebruary 11, 2023 | marketwatch.comBicycle Trailers Market With Massive Data and Availability to Hamper the Industry Growth | 115 Pages ReportFebruary 10, 2023 | marketwatch.comBicycle Modification Parts Market is expected to witness Incredible Growth during 2023-2028February 10, 2023 | marketwatch.comBicycle Accessories Market Opportunity, Size, Share, Growth, Segmentation, In-depth Analysis Research Report 2023-2028February 10, 2023 | marketwatch.comBicycle Infotainment System Market 2023 Structure Along With Size, Trends, Revenue, Market segments, Forecast to 2029February 10, 2023 | marketwatch.comBicycle Carbon Frames Market Size 2023 With End-user Industries, Segments Covered in the ReportFebruary 9, 2023 | marketwatch.comBicycle Brake Fluid Market [2023-2028] | Latest Study on Industry Trends & Forecast with Top Countries DataFebruary 9, 2023 | marketwatch.comElectric Bicycle Mid-drive Motor Market Global Demand, Opportunities, Trends, Analysis and Forecast to 2028February 9, 2023 | marketwatch.comBicycle Tubeless Tire Market Report Covers Latest Market Trends, Drivers & Restraints, Key Players, Strategies And R&D Investments Upto 2028February 8, 2023 | marketwatch.comShared Bicycle Service Market Size with Global Industry Analysis, Revenue, Future Growth, Business Prospects and Forecast 2023 to 2029February 8, 2023 | marketwatch.comBicycle Crankset Markets Industry Analysis Database for Period from 2023-2026See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive BCYC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address BCYC Company Calendar Last Earnings11/03/2021Today3/28/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BCYC CUSIPN/A CIK1761612 Webwww.bicycletherapeutics.com Phone441223261503FaxN/AEmployees119Year FoundedN/APrice Target and Rating Average Stock Price Forecast$51.36 High Stock Price Forecast$74.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+136.5%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($3.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,720,000.00 Net Margins-779.35% Pretax Margin-789.89% Return on Equity-37.51% Return on Assets-26.02% Debt Debt-to-Equity Ratio0.11 Current Ratio6.92 Quick Ratio6.92 Sales & Book Value Annual Sales$14.46 million Price / Sales32.01 Cash FlowN/A Price / Cash FlowN/A Book Value$9.12 per share Price / Book2.38Miscellaneous Outstanding Shares21,310,000Free Float19,388,000Market Cap$462.85 million OptionableNot Optionable Beta0.77 Key ExecutivesKevin LeeChief Executive Officer & Executive DirectorLee H. KalowskiPresident & Chief Financial OfficerAlistair MilnesChief Operating OfficerMichael SkynnerChief Technology OfficerNicholas KeenChief Scientific OfficerKey CompetitorsBiomea FusionNASDAQ:BMEAMacroGenicsNASDAQ:MGNXAldeyra TherapeuticsNASDAQ:ALDXEdgewise TherapeuticsNASDAQ:EWTXMersana TherapeuticsNASDAQ:MRSNView All CompetitorsInsiders & InstitutionsVoya Investment Management LLCSold 1,707 shares on 2/28/2023Ownership: 0.310%NatixisBought 3,613 shares on 2/24/2023Ownership: 0.017%Alliancebernstein L.P.Bought 9,111 shares on 2/16/2023Ownership: 0.244%First Light Asset Management LLCSold 8,289 shares on 2/15/2023Ownership: 2.346%Legal & General Group PlcBought 1,400 shares on 2/15/2023Ownership: 0.035%View All Insider TransactionsView All Institutional Transactions BCYC Stock - Frequently Asked Questions Should I buy or sell Bicycle Therapeutics stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BCYC shares. View BCYC analyst ratings or view top-rated stocks. What is Bicycle Therapeutics' stock price forecast for 2023? 13 brokerages have issued 1 year price targets for Bicycle Therapeutics' shares. Their BCYC share price forecasts range from $30.00 to $74.00. On average, they expect the company's stock price to reach $51.36 in the next twelve months. This suggests a possible upside of 136.5% from the stock's current price. View analysts price targets for BCYC or view top-rated stocks among Wall Street analysts. How have BCYC shares performed in 2023? Bicycle Therapeutics' stock was trading at $29.60 at the start of the year. Since then, BCYC stock has decreased by 26.6% and is now trading at $21.72. View the best growth stocks for 2023 here. When is Bicycle Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our BCYC earnings forecast. How were Bicycle Therapeutics' earnings last quarter? Bicycle Therapeutics plc (NASDAQ:BCYC) posted its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.59) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.02. The firm had revenue of $4.33 million for the quarter, compared to analyst estimates of $5.29 million. Bicycle Therapeutics had a negative net margin of 779.35% and a negative trailing twelve-month return on equity of 37.51%. What ETFs hold Bicycle Therapeutics' stock? ETFs with the largest weight of Bicycle Therapeutics (NASDAQ:BCYC) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Harbor Disruptive Innovation ETF (INNO), Harbor Health Care ETF (MEDI), First Trust IPOX Europe Equity Opportunities ETF (FPXE), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ).ProShares Ultra Nasdaq Biotechnology (BIB). What other stocks do shareholders of Bicycle Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC). When did Bicycle Therapeutics IPO? (BCYC) raised $64 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity was co-manager. What is Bicycle Therapeutics' stock symbol? Bicycle Therapeutics trades on the NASDAQ under the ticker symbol "BCYC." Who are Bicycle Therapeutics' major shareholders? Bicycle Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (3.40%), Morgan Stanley (2.43%), First Light Asset Management LLC (2.35%), Verition Fund Management LLC (1.28%), Price T Rowe Associates Inc. MD (1.14%) and Soleus Capital Management L.P. (0.87%). Insiders that own company stock include Kate Bingham, Kevin Lee, Lee Kalowski, Nicholas Keen, Nigel Crockett, Pierre Legault, Plc Glaxosmithkline and Stephen B Alexander. View institutional ownership trends. How do I buy shares of Bicycle Therapeutics? Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bicycle Therapeutics' stock price today? One share of BCYC stock can currently be purchased for approximately $21.72. How much money does Bicycle Therapeutics make? Bicycle Therapeutics (NASDAQ:BCYC) has a market capitalization of $462.85 million and generates $14.46 million in revenue each year. The company earns $-112,720,000.00 in net income (profit) each year or ($3.80) on an earnings per share basis. How many employees does Bicycle Therapeutics have? The company employs 119 workers across the globe. How can I contact Bicycle Therapeutics? Bicycle Therapeutics' mailing address is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. The official website for the company is www.bicycletherapeutics.com. The company can be reached via phone at 441223261503 or via email at david.borah@bicycletx.com. This page (NASDAQ:BCYC) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.